300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Enterprise Software
Local
Platforms
Health Care
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Automotive
Education
Medical Device
eSports
Biotechnology
Sports
Renewable Energy
Legal
Facebook
Blockchain
Software
Medical
Infrastructure
Web3
Venture Capital
Beauty
Theatre
Fashion
Recruiting
Social
Celebrity
Crowdfunding
LGBT
Climate
Wine and Spirits
Cannabis
Art
Music
Mobile Apps
Real Estate
Sporting Goods
Life Science
FinTech
Food and Beverage
Finance
Digital Media
Publishing
Manufacturing
Social Media
Franchise
Financial Services
Non Profit
Internet
Android
Mobile Advertising
Sustainability
Enterprise
Proptech
Hardware
Community
Impact
Media (Entertainment)
Transportation
Biotech
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Burkina Faso
LATAM
Sweden
Hong Kong
Nigeria
Brazil
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Africa
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Sudan
Pakistan
Russian Federation
Tajikistan
Zambia
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Colombia
Armenia
China
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Sierra Leone
Philippines
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Rwanda
Malaysia
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Argentina
Cyprus
Spain
Qatar
Barbados
Belgium
Bangladesh
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Faroe Islands
Bulgaria
Estonia
Bolivia
Belize
Algeria
Belarus
Bahrain
Finland
Italy
Hungary
Bahamas
Israel
Grenada
Honduras
Iceland
Jersey
Lithuania
Liechtenstein
Cambodia
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Life Science Startup Investors in Asia (October 2026)

The most active venture capital funds and angel investors investing in Asia Life Science startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Asia Life Science startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
Prox Ventures
VC Fund
10 China, United States, United Kingdom Seed, Series A Medical, Biotechnology, Health Care $2.5M–$30M
Qiming Venture Partners
VC Fund
8 China, United States, Hong Kong Series B, Series A, Series C Health Care, Biotechnology, Medical $4.3M–$120M
Mitsubishi UFJ Capital
VC Fund
7 Japan, United States, Israel Series A, Venture - Series Unknown, Seed Software, Information Technology, Manufacturing $470k–$21M
SMBC Venture Capital
VC Fund
6 Japan, United States, Singapore Venture - Series Unknown, Series A, Series B Information Technology, Software, Health Care $800k–$34M
Hillhouse Investment
VC Fund
6 China, United States, Singapore Series B, Series A, Series C Biotechnology, Health Care, Software $2.9M–$230M
IT-Farm
VC Fund
6 United States, Japan, Germany Seed, Series A, Series B Software, Health Care, Medical $1M–$36M
HSG
VC Fund
6 China, United States, Singapore Series A, Series B, Seed Artificial Intelligence, Software, Health Care $2M–$200M
Linear Capital
VC Fund
6 China, Singapore, United States Seed, Angel, Series A Artificial Intelligence, Software, Manufacturing $1.4M–$122M
UTEC - The University of Tokyo Edge Capital Partners
VC Fund
6 Japan, United States, India Series A, Seed, Venture - Series Unknown Health Care, Biotechnology, Medical $624k–$18M
Huagai Capital
VC Fund
5 China, United States, Hong Kong Series A, Series B, Angel Health Care, Biotechnology, Medical $444k–$90M
Lenovo Capital
VC Fund
5 China, Hong Kong, United States Series A, Seed, Series B Manufacturing, Artificial Intelligence, Software $1.4M–$150M
Nissay Capital
VC Fund
5 Japan, United States, Ethiopia Venture - Series Unknown, Seed, Series A Health Care, Software, Medical $455k–$12M
SBI Investment
VC Fund
5 Japan, United States, South Korea Series B, Series A, Venture - Series Unknown Software, Information Technology, Financial Services $1.3M–$62M
Hillhouse Ventures
VC Fund
5 China, Singapore, Norway Series A, Series B, Seed Manufacturing, Biotechnology, Health Care $10M–$120M
DG Daiwa Ventures
VC Fund
5 Japan, United States, India Seed, Series A, Venture - Series Unknown Software, FinTech, Artificial Intelligence $367k–$19M
Matrix Partners China
VC Fund
4 China, United States, Singapore Series A, Series B, Seed Health Care, Software, Information Technology $1.2M–$137M
Osaka University Venture Capital
VC Fund
4 Japan Seed, Venture - Series Unknown, Series A Biotechnology, Health Care, Medical $480k–$19M
Miyako Capital
VC Fund
4 Japan, United States, United Kingdom Series A, Seed, Series B Medical, Biotechnology, Information Technology $395k–$150M
Baidu Ventures
VC Fund
4 China, United States, Singapore Series A, Seed, Series B Artificial Intelligence, Health Care, Robotics $1.5M–$123M
Vinno Capital
VC Fund
4 China, United States Series A, Seed, Series B Manufacturing, Semiconductor, Medical $1.4M–$139M
UntroD Capital
VC Fund
4 Japan, Singapore, Austria Seed, Venture - Series Unknown, Series A Manufacturing, Biotechnology, Health Care $316k–$15M
Dalton Venture
VC Fund
4 China, India, Canada Seed, Series A, Series B Health Care, Medical, Biotechnology $512k–$50M
EFung Capital
VC Fund
4 China, United States, India Series A, Series B, Series C Health Care, Biotechnology, Medical $1.4M–$100M
Angel Bridge
VC Fund
3 Japan Series A, Seed, Series B Information Technology, Software, Consulting $792k–$47M
Lilly Asia Ventures
VC Fund
3 China, United States, Hong Kong Series A, Series B, Series C Biotechnology, Health Care, Medical $14M–$308M
Nippon Venture Capital
VC Fund
3 Japan, United States, Indonesia Venture - Series Unknown, Series A, Series B Health Care, Software, Medical $457k–$45M
ASBV
VC Fund
3 China, Australia, Hong Kong Seed, Series A, Angel Health Care, Medical, Biotechnology $471k–$34M
CD Capital
VC Fund
3 China, United States Series A, Series B, Seed Health Care, Biotechnology, Medical Device $1.4M–$34M
Incubate Fund
VC Fund
3 Japan, United States, India Seed, Series A, Venture - Series Unknown Software, Information Technology, Artificial Intelligence $288k–$20M
EDBI
VC Fund
3 United States, Singapore, United Kingdom Series C, Series B, Series D Software, Biotechnology, Health Care $10M–$400M
Legend Capital
VC Fund
3 China, United States, South Korea Series B, Series A, Series C Health Care, Medical, Biotechnology $2.9M–$200M
Sherpa Healthcare Partners
VC Fund
3 China, United States, Kenya Series A, Series B, Series C Biotechnology, Health Care, Medical $7.2M–$128M
Haitang Fund
VC Fund
3 China Seed, Series A, Venture - Series Unknown Manufacturing, Biotechnology, Medical $1.5M–$103M
OrbiMed
VC Fund
3 United States, China, Israel Series B, Series A, Series C Biotechnology, Health Care, Pharmaceutical $9M–$160M
CITIC Capital Holdings
VC Fund
3 China, United States, Japan Series A, Series B, Series C Manufacturing, Health Care, Biotechnology $3.2M–$230M
Anzu Partners
VC Fund
3 United States, Canada, Spain Series A, Series B, Venture - Series Unknown Software, Biotechnology, Manufacturing $5M–$44M
MiraclePlus
VC Fund
3 China, United States, Singapore Seed, Angel, Pre-Seed Artificial Intelligence, Software, Information Technology
WuXi AppTec
VC Fund
3 United States, China, Israel Series A, Series B, Series C Biotechnology, Health Care, Pharmaceutical $6M–$187M
Cenova
VC Fund
3 China, United States, Hong Kong Series B, Series A, Series C Medical, Health Care, Biotechnology $2.9M–$100M
Northern Light Venture Capital
VC Fund
3 China, United States, South Korea Series A, Series B, Venture - Series Unknown Health Care, Medical, Biotechnology $1.5M–$60M
Entrepreneurship Relay Group
VC Fund
3 China Series A, Angel, Venture - Series Unknown Manufacturing, Software, Enterprise $1.5M–$30M
Tianjin Venture Capital
VC Fund
3 China, United States Seed, Series A Manufacturing, Information Technology, Biotechnology $202k–$31M
Longpan Investment
VC Fund
3 China, United States, Cayman Islands Series A, Seed, Series B Health Care, Medical, Biotechnology $14M–$60M
Senshu Ikeda Capital
VC Fund
3 Japan Venture - Series Unknown, Series A, Seed Software, Manufacturing, Internet $395k–$17M
Shenzhen Capital Group
VC Fund
3 China, United States, Japan Series A, Series B, Series C Manufacturing, Health Care, Software $1.5M–$156M
Oriental Fortune Capital
VC Fund
3 China, United States, Hong Kong Series A, Series B, Seed Manufacturing, Software, Artificial Intelligence $1.5M–$100M
ULTIMA
VC Fund
3 China Angel, Series A, Series B Health Care, Biotechnology, Fitness $462k–$15M
JAFCO
VC Fund
3 Japan, United States, India Series A, Series B, Venture - Series Unknown Information Technology, Software, Artificial Intelligence $1.4M–$41M
Keio Innovation Initiative
VC Fund
3 Japan, United Kingdom Series A, Seed, Venture - Series Unknown Health Care, Medical, Biotechnology $826k–$41M
Japan Science and Technology Agency
VC Fund
3 Japan Series A, Seed, Venture - Series Unknown Biotechnology, Medical, Manufacturing $975k–$15M
Access all 50 investors in Asia Life Science startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

Prox Ventures
VC Fund · Shanghai, Shanghai, China · 10 investments in Asia Life Science startups

Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential. They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many years of remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.

Show more...

Investment focus

  • Industry: Medical, Biotechnology, Health Care
  • Stage:Seed, Series A
  • Geography: China, United States, United Kingdom

Investor stats

  • Total investments: 83
  • Round size: Seed $2.5M–$30M; Series A $3M–$28M
  • Lead/follow: 18% lead, 82% follow

Portfolio highlights

  • BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
  • Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
  • Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Show all investments...

Qiming Venture Partners
VC Fund · Shanghai, Shanghai, China · 8 investments in Asia Life Science startups

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages. Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 1200
  • Round size: Series A $4.3M–$48M; Series B $8M–$90M; Series C $12M–$120M
  • Lead/follow: 51% lead, 49% follow
  • Last fund: Likely actively investing — fresh fund, raised $8M in 2026

Portfolio highlights

  • Nice Tuan — Nice Tuan is an e-commerce platform that provides daily groceries and miscellaneous products.
  • Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
  • Shennapsi Artificial Intelligence Technology — Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterolmonitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Show all investments...

Mitsubishi UFJ Capital
VC Fund · Tokyo, Tokyo, Japan · 7 investments in Asia Life Science startups

Mitsubishi UFJ Capital is a venture capital firm focusing on life science, ICT, and high technology investments.

Show more...

Investment focus

  • Industry: Software, Information Technology, Manufacturing
  • Stage:Series A, Venture - Series Unknown, Seed
  • Geography: Japan, United States, Israel

Investor stats

  • Total investments: 689
  • Round size: Seed $470k–$16M; Series A $1.2M–$21M; Venture - Series Unknown $525k–$11M
  • Lead/follow: 10% lead, 90% follow
  • Last fund: May invest from a new fund soon — raised $94M in 2020

Portfolio highlights

  • Smart Craft —
  • Luxna Biotech — Luxana Biotech is a biotechnology firm dedicated to promoting the practical use of safe and effective nucleic acid therapies. Utilizing nucleic acid chemistry technology, the company strives to provide nucleic acid medicines to patients suffering from diseases that currently lack effective treatments.
  • Link Therapeutics — Link Therapeutics specializes in developing therapeutic methods for targeting autoantibodies and identifying pathogenic autoantibodies.
Show all investments...

SMBC Venture Capital
VC Fund · Tokyo, Tokyo, Japan · 6 investments in Asia Life Science startups

Sumitomo Mitsui Banking Corporation (SMBC) and its group companies offer a broad range of financial services centered on banking. They are also engaged in the leasing, securities, credit card, investment, mortgage securitization, venture capital and other credit related businesses. The following lists the activities of SMBC, its subsidiaries and affiliates in the various business segments.

Show more...

Investment focus

  • Industry: Information Technology, Software, Health Care
  • Stage:Venture - Series Unknown, Series A, Series B
  • Geography: Japan, United States, Singapore

Investor stats

  • Total investments: 672
  • Round size: Series A $1.1M–$32M; Series B $2.3M–$34M; Venture - Series Unknown $800k–$12M
  • Lead/follow: 4% lead, 96% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • LQUOM — QWAVE offers cryptography communication technology.
  • Etaily — Etaily provides e-commerce and retail solutions in the Philippines, enabling brands with end-to-end services, from store management to fulfillment.
  • Link Therapeutics — Link Therapeutics specializes in developing therapeutic methods for targeting autoantibodies and identifying pathogenic autoantibodies.
Show all investments...

Hillhouse Investment
VC Fund · Changyang, Beijing, China · 6 investments in Asia Life Science startups

Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 331
  • Round size: Series A $2.9M–$165M; Series B $15M–$230M; Series C $15M–$220M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: May invest from a new fund soon — raised $11B in 2018

Portfolio highlights

  • Sainte — Sainte is a company which provides professional nutritional solutions for babies with different nutritional needs
  • Vita Dynamics — Vita Dynamics involves learning through real-world interactions by developing robots that can physically engage with their environment, they can adapt more naturally and efficiently.
  • NeueHCT — Horizon Continental Technology is a joint venture between Continental Group and Horizon Robotics
Show all investments...

IT-Farm
VC Fund · Tokyo, Tokyo, Japan · 6 investments in Asia Life Science startups

IT-Farm is a venture capital firm which specializes in seed, start-up, and early stage companies. It primarily invests in mobile, big-data, connected car, IoT, OTT service, Helth care, Bio Tech and other IT industries. The firm actively invests in SF bay area and Japan, as well as other geometries including Asia and Europe. We support portfolio companies, especially on the partnership with Japanese enterprises.

Show more...

Investment focus

  • Industry: Software, Health Care, Medical
  • Stage:Seed, Series A, Series B
  • Geography: United States, Japan, Germany

Investor stats

  • Total investments: 135
  • Round size: Seed $1M–$7.5M; Series A $1.6M–$16M; Series B $2.5M–$36M
  • Lead/follow: 10% lead, 90% follow
  • Last fund: May invest from a new fund soon — last raise in 2021

Portfolio highlights

  • Ubitus — As cloud gaming enablers, Ubitus' GPU virtualization, Streaming technology and hybrid cloud deployment can serve different kinds of solutions for Telco, Game companies to quick enter cloud gaming market. Moreover, Ubitus provide Global distribution and New Media content solution for new media studio and fashion brand to help them distribute rich media contents worldwide.
  • BitBiome — BitBiome is a biotechnology company focused on analyzing microbial genomes and discovering enzymes and proteins that can be applied across industries such as pharmaceuticals, food production, and sustainable manufacturing. The company uses single-cell microbial sequencing technology to study microbes that are difficult to culture throughconventional laboratory methods, enabling the creation of a large microbial genome database called bit-GEM. Its platform supports enzyme discovery, genome analysis, and bioengineering efforts aimed at developing bio-based alternatives for industrial processes. bitBiome also works with academic institutions and commercial partners on research projects involving areas such as biodegradable materials, biomass conversion, and pharmaceutical ingredient synthesis. The company positions microbes as a resource for advancing the bioeconomy by providing tools and data that support biotechnology research and industrial applications.
  • POPS Worldwide — POPS Worldwide is the leading digital entertainment company in Southeast Asia. With over 4 billion monthly views of its music and entertainment content, POPS is the fastest growing digital entertainment media company with hundreds of artists, content creators and partners from broadcast television, publishing and production in the POPS Network.POPS also produces a wide variety of original content for its industry-leading owned and operated channels like POPS Music, POPS Kids, POPS TV, Beauty Me, HerVoice and CoolTV that target highly sought after demographics: teens, kids, women and men.
Show all investments...

HSG
VC Fund · Hong Kong, Hong Kong Island, Hong Kong · 6 investments in Asia Life Science startups

HSG is a leading venture capital and private equity firm investing globally in the technology, healthcare, and consumer sectors.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Software, Health Care
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 1091
  • Round size: Seed $2M–$50M; Series A $3.1M–$100M; Series B $11M–$200M
  • Lead/follow: 45% lead, 55% follow
  • Last fund: Likely still investing — raised $2.5B in 2024

Portfolio highlights

  • Z.ai — Z.ai develops artificial intelligence models and services built upon large-scale pretrained architectures. The company offers ChatGLM, a dialogue-focused language model series designed for smooth conversation and easy integration. It also provides Ying, a text-to-video model capable of generating short video clips from text or images, and AutoGLM,a voice-driven AI agent that performs smartphone tasks based on complex user instructions. Z.ai supports integration through an API platform and offers migration assistance for developers moving from other AI ecosystems. The company’s technology stems from research at Tsinghua University’s KEG lab and emphasizes general-purpose cognitive intelligence models.
  • Xinghuo Chenguang — Xinghuo Chenguang is a hard-tech company focusing on semiconductor chips and optoelectronic interconnect technologies.
  • Suisheng Technology — Suisheng Technology is an innovative company specializing in AI-driven memory services, dedicated to developing intelligent solutions that help individuals and businesses capture, organize, and retrieve important information with greater efficiency and precision.
Show all investments...

Linear Capital
VC Fund · Shanghai, Shanghai, China · 6 investments in Asia Life Science startups, 27 in the past 12 months

Linear Capital is a Frontier Tech Fund founded in 2014 by Harry Wang, Facebook's first Chinese R&D manager. We currently manage 10 funds with AUM of more than $2 billion.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Software, Manufacturing
  • Stage:Seed, Angel, Series A
  • Geography: China, Singapore, United States

Investor stats

  • Total investments: 96
  • Round size: Seed $1.4M–$122M; Angel $1.4M–$122M; Series A $5.7M–$29M
  • Lead/follow: 30% lead, 70% follow
  • Last fund: Likely still investing — raised $300M in 2022

Portfolio highlights

  • D-Robotics — Accelerate development with D-Robotics RDK developer kits & open-source tools for edge AI & embodied robotics. Boost performance up to 128 TOPS. Shop now!
  • Xieyue Intelligent — Xieyue Intelligent focuses on the research and development of embodied intelligence technology.
  • DeepPu Intelligence — DeepPu Intelligence is a high-tech enterprise specializing in the research, development, and innovation of intelligent robotic technologies. The company focuses on creating advanced robotic systems that integrate artificial intelligence, machine vision, and automation to serve a wide range of industries, including manufacturing, logistics,healthcare, and service sectors.
Show all investments...

UTEC - The University of Tokyo Edge Capital Partners
VC Fund · Tokyo, Tokyo, Japan · 6 investments in Asia Life Science startups

UTEC-The University of Tokyo Edge Capital Partners Co., Ltd.. UTEC is a seed/early stage technology focused venture capital firm associated with The University of Tokyo.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Seed, Venture - Series Unknown
  • Geography: Japan, United States, India

Investor stats

  • Total investments: 215
  • Round size: Seed $624k–$12M; Series A $2.3M–$18M; Venture - Series Unknown $2.2M–$13M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: Likely actively investing — fresh fund, raised $326M in 2025

Portfolio highlights

  • Mujin — At Mujin, we design automation platforms to enhance any robot, enable advanced capabilities and lower operating costs.
  • RegCell — RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer .
  • United Immunity — Just another WordPress site
Show all investments...

Huagai Capital
VC Fund · Beijing, Beijing, China · 5 investments in Asia Life Science startups, 10 in the past 12 months

Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Angel
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 154
  • Round size: Angel $444k–$15M; Series A $1.5M–$73M; Series B $8.5M–$90M
  • Lead/follow: 41% lead, 59% follow
  • Last fund: May invest from a new fund soon — raised $430M in 2018

Portfolio highlights

  • SeaArt — SeaArt AI is an all-in-one AI creativity community for art, videos, audio, and AI chats, where creators collaborate, spark inspiration, and grow together.
  • Zhiran Medical — Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology.
  • Allygen Biologics — Allygen Biologics is a biotechnology company that provides research and development of targeted conjugate therapeutics.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Lenovo Capital
VC Fund · Beijing, Beijing, China · 5 investments in Asia Life Science startups

Lenovo Capital and Incubator Group is an accelerator and venture capital firm.

Show more...

Investment focus

  • Industry: Manufacturing, Artificial Intelligence, Software
  • Stage:Series A, Seed, Series B
  • Geography: China, Hong Kong, United States

Investor stats

  • Total investments: 347
  • Round size: Seed $1.4M–$65M; Series A $1.5M–$74M; Series B $8M–$150M
  • Lead/follow: 26% lead, 74% follow
  • Last fund: May invest from a new fund soon — raised $500M in 2016

Portfolio highlights

  • SemiGraph — SemiGraph focuses on the research, development, and implementation of "3D intelligent interaction + ultimate aesthetics."
  • Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
  • SenseTime Medical — SenseTime Medical promotes the development and implementation of its medical big model and provides smart health solutions.
Show all investments...

Nissay Capital
VC Fund · Tokyo, Tokyo, Japan · 5 investments in Asia Life Science startups

Nissay Capital is a venture capital Company specializing in seed, start-up, growth capital, middle stage, and later stage investment.

Show more...

Investment focus

  • Industry: Health Care, Software, Medical
  • Stage:Venture - Series Unknown, Seed, Series A
  • Geography: Japan, United States, Ethiopia

Investor stats

  • Total investments: 327
  • Round size: Seed $455k–$9.6M; Series A $1.2M–$12M; Venture - Series Unknown $899k–$7M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: May invest from a new fund soon — raised $92M in 2019

Portfolio highlights

  • Indent — Indent creates products that help writers create original works such as novels, manga, screenplays, and game scenarios. They will work to create an environment in which artists can focus on their creations and enjoy sharing their work.
  • Spectronix — Spectronics is a development of new technologies and new applications to bring about innovation, focusing on the future of laser technology.
  • Zeal Boxing Fitness — Zeal Boxing Fitness combines power of sports with the power of technology to provide a service that allows to enjoy fitness.
Show all investments...

SBI Investment
VC Fund · Minato, Chiba, Japan · 5 investments in Asia Life Science startups

SBI Investment supports the business development and growth of private venture companies through fund investment. It manages and manages venture capital funds under the management philosophy of becoming a leading company responsible for the creation and development of core industries in the 21st century as a "new industry creator". SBI Investment has invested in a total of 986 companies in the past, of which 169 (17.1% of investment companies) have exited through IPO or M & A.

Show more...

Investment focus

  • Industry: Software, Information Technology, Financial Services
  • Stage:Series B, Series A, Venture - Series Unknown
  • Geography: Japan, United States, South Korea

Investor stats

  • Total investments: 456
  • Round size: Series A $1.9M–$28M; Series B $4.5M–$62M; Venture - Series Unknown $1.3M–$20M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: May invest from a new fund soon — raised $77M in 2020

Portfolio highlights

  • LQUOM — QWAVE offers cryptography communication technology.
  • Alxtal — Alxtal is a tech company who optimize the development, design, and manufacturing processes of the manufacturing industry with IT and AI.
  • Zerodoor HD — Zerodoor HD specializes in digital transformation in constructing industry.
Show all investments...

Hillhouse Ventures
VC Fund · Singapore, Central Region, Singapore · 5 investments in Asia Life Science startups

Hillhouse Venture Capital is an investment institution established by Hillhouse Capital that focuses on investing in early-stage startups.

Show more...

Investment focus

  • Industry: Manufacturing, Biotechnology, Health Care
  • Stage:Series A, Series B, Seed
  • Geography: China, Singapore, Norway

Investor stats

  • Total investments: 77
  • Round size: Seed $10M–$120M; Series A $10M–$85M; Series B $14M–$99M
  • Lead/follow: 44% lead, 56% follow

Portfolio highlights

  • Yatsen Holding — Yasten provides high-quality fashion makeup products.
  • kaye technology — Kaye Technology is a company that provides automation upgrade solutions for beverage equipment.
  • Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
Show all investments...

DG Daiwa Ventures
VC Fund · Marunouchi, Tokyo, Japan · 5 investments in Asia Life Science startups, 13 in the past 12 months

DG Daiwa Ventures invests in start-up companies with next-generation technology and provides business development support. It is focused on blockchain, xR, AI, security, and BioHealth, as they are likely to be at the foundations of future businesses. In addition to the five core technologies, the fund will also focus on IoT technologies, which often overlap or serve as an application layer.

Show more...

Investment focus

  • Industry: Software, FinTech, Artificial Intelligence
  • Stage:Seed, Series A, Venture - Series Unknown
  • Geography: Japan, United States, India

Investor stats

  • Total investments: 89
  • Round size: Seed $679k–$6M; Series A $3M–$10M; Venture - Series Unknown $367k–$19M
  • Lead/follow: 19% lead, 81% follow
  • Last fund: May invest from a new fund soon — last raise in 2020

Portfolio highlights

  • New Chat — New Chat is a technology company that develops communication software focused on visual and interactive group interactions. The company builds platforms designed to help small, close-knit groups of people share daily experiences through short-form multimedia content. Its primary software automates the creation of collaborative video logs byprompting users for brief, periodic updates throughout the day. By structuring messaging around shared visual moments, the business aims to provide an alternative to traditional text-based group chats and standard social media networking.
  • First Coffee — Discover the best specialty coffee in India with our range of single origin Arabica beans and exclusive merchandise. Shop online at First Coffee for freshly roasted, quality blends.
  • Tellus Global — Tellus Global is a company focused on creating new businesses using satellite data, AI, and software technologies,Its core mission is to make satellite information accessible and useful across industries such as agriculture, environmental conservation, construction, finance, and disaster management.
Show all investments...

Matrix Partners China
VC Fund · Beijing, Beijing, China · 4 investments in Asia Life Science startups

Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies. Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have gone on to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors. Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.

Show more...

Investment focus

  • Industry: Health Care, Software, Information Technology
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 712
  • Round size: Seed $1.2M–$74M; Series A $2.9M–$52M; Series B $10M–$137M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: Likely still investing — raised $92M in 2023

Portfolio highlights

  • Camera360 — Camera360 is a mobile phone camera application. Through a variety of solutions, including Camera360 Ultimate, HelloCamera, Movie360, Pink360, Camera360 Cloud, Camera360 SDK and Web Camera360, Camera360 hopes to build an ecosystem for the modern creatives to capture, compose and share the beautiful moments of their lives.
  • DiffuSpace — DiffuSpace is an artificial intelligence initiative dedicated to building diffusion language models to establish a new foundation model paradigm beyond traditional autoregression. Instead of generating text sequentially token by token, their technology focuses on thinking globally and evolving through uncertainty.
  • Liepin — Liepin is the largest and most professional high-end talent community-based recruitment site, with its innovative products and unique service model model for create an interactive high-end talent recruitment platform between business, headhunting and workplace. Tens of thousands of professional executive search consultant for businesses and jobseekers set up communication between the bridge and accelerate corporate recruitment process, recommended paying jobs in the workplace, career development planning. 16 job seekers to avoid the risk of privacy protection, millions of high-end elite member libraries, help enterprises development needs.
Show all investments...

Osaka University Venture Capital
VC Fund · Osaka, Osaka, Japan · 4 investments in Asia Life Science startups

Osaka University Venture Capital is a venture capital firm that focuses on early-stage ventures in the fields of life innovation, green innovation, and platform technology. The firm was founded in 2014 and based in Osaka, Japan.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Venture - Series Unknown, Series A
  • Geography: Japan

Investor stats

  • Total investments: 93
  • Round size: Seed $480k–$4.5M; Series A $1.5M–$19M; Venture - Series Unknown $751k–$3.5M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: May invest from a new fund soon — raised $92M in 2021

Portfolio highlights

  • JiMED — JiMED designs & develops AI based brain-computer interface for implant in ALS patients to improve communication.
  • LQUOM — QWAVE offers cryptography communication technology.
  • RegCell — RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer .
Show all investments...

Miyako Capital
VC Fund · Kyoto, Kyoto, Japan · 4 investments in Asia Life Science startups

Miyako Capital is the venture capital that manages Kyoto University 2nd Venture Fund (KUVF). The company was founded in 2013 and based in Kyoto & Tokyo, Japan. Investment fields are: 1) Life Science, Biotechnology: Drug creation, regenerative medicine, medical beauty equipment, medical services. 2) Agri-Food: Industrialization, agricultural and fishery products growth-promoting technology, specified health food, health food. 3) Environment, Energy: Alternative energy, and related technologies. 4) IT, Electronics: Web, mobile related devices and application, telecommunication technology, security, consumer and business oriented application, mechatronic, robot. 5) New services utilizing state-of-art technology. Investment stages: Primary investment stages are initial-growth stages of seed and early. However, we aim at all growth stages and make investment in post-IPO portfolio companies as well as public companies that are related with Kyoto University.

Show more...

Investment focus

  • Industry: Medical, Biotechnology, Information Technology
  • Stage:Series A, Seed, Series B
  • Geography: Japan, United States, United Kingdom

Investor stats

  • Total investments: 54
  • Round size: Seed $395k–$19M; Series A $2M–$21M; Series B $3.7M–$150M
  • Lead/follow: 19% lead, 81% follow
  • Last fund: May invest from a new fund soon — raised $91M in 2019

Portfolio highlights

  • Mui Lab — Mui is an aesthetically-pleasing wooden IoT device connected to a cloud service. By accessing information through natural wood, we can rethink a new type of lifestyle.
  • Fermelanta — Fermelanta produces rare plant-based ingredients through microbial fermentation. It engineers a cell to build a biosynthetic pathway of target molecules with gene transfer and disruption.
  • United Immunity — Just another WordPress site
Show all investments...

Baidu Ventures
VC Fund · Beijing, Beijing, China · 4 investments in Asia Life Science startups

Doma Protocol is a purpose-built blockchain to modernize and unlock the liquidity of over 362M existing and future domains

Show more...

Investment focus

  • Industry: Artificial Intelligence, Health Care, Robotics
  • Stage:Series A, Seed, Series B
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 243
  • Round size: Seed $1.9M–$28M; Series A $1.5M–$43M; Series B $8M–$123M
  • Lead/follow: 22% lead, 78% follow
  • Last fund: Likely still investing — raised $141M in 2023

Portfolio highlights

  • Sondit — Sondit specializes in R&D and manufacturing of civilian radar systems. It includes intelligent transportation, intelligent security, vehicle-road coordination, and other fields. It engaged in traffic information monitoring and urban traffic management in the field of the intelligent transportation industry.
  • Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
  • Differential Robotics — Differential Robotics is a robotics company providing research, design, and development of aerial robots and intelligent autonomous drones.
Show all investments...

Vinno Capital
VC Fund · Shenzhen, Guangdong, China · 4 investments in Asia Life Science startups

Vinno Capital focuses on early-stage venture investments in ICT and healthcare-related fields.

Show more...

Investment focus

  • Industry: Manufacturing, Semiconductor, Medical
  • Stage:Series A, Seed, Series B
  • Geography: China, United States

Investor stats

  • Total investments: 42
  • Round size: Series A $1.4M–$70M; Series B $11M–$139M
  • Lead/follow: 48% lead, 52% follow

Portfolio highlights

  • CiMicro.Ai — CiMicro.ai is an AI‑chip startup building compute‑in‑memory (CiM)‑based heterogeneous accelerators for high‑efficiency, low‑cost large‑language‑model inference.
  • Ruimeng Semiconductor — Ruimeng Semiconductor is a provider of intelligent human-machine interface processor chips and solutions.
  • Baisheng Smart Computing — Baisheng Smart Computing specializes in the field of information technology application innovation, operations, and maintenance.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
UntroD Capital
VC Fund · Sumida, Tokyo, Japan · 4 investments in Asia Life Science startups, 11 in the past 12 months

UntroD Capital is an R&D-based innovative technology that specializes in social implementation.

Show more...

Investment focus

  • Industry: Manufacturing, Biotechnology, Health Care
  • Stage:Seed, Venture - Series Unknown, Series A
  • Geography: Japan, Singapore, Austria

Investor stats

  • Total investments: 148
  • Round size: Seed $316k–$6M; Series A $2.1M–$15M; Venture - Series Unknown $438k–$10M
  • Lead/follow: 42% lead, 58% follow
  • Last fund: Likely still investing — fund raised in 2024

Portfolio highlights

  • JAOPS — JAOPS is dedicated to Operations as a Service and develops software, tools, and services for space mission operations, including data processing, mission planning, context evaluation, anomaly resolution, and real-time mission control and monitoring. The company provides mission operations design, training, and certification for operators, astronauts, and ground segment teams. JAOPS offers products such as Yamcs Gateway, mission control tools, and simulation environments to support spacecraft and lunar rover missions. Its services include turnkey mission control center design and deployment, operational reviews, and operations as a service. JAOPS works with open-source platforms like Yamcs, Grafana, and robotics simulators to support Earth orbit, cislunar, and lunar surface missions.
  • Eco-Pork — Eco-Pork is a co-creation solution farm that supports farmers' food productivity improvement. It is connecting the pig and technology, pork ( Pork ) new business ecosystems ( Ecosystem By building a), in the pork growing demand around the world, to get the most out of the food supply capacity is finite.
  • Teragen Energy — Teragen Energy develops an energy technology platform based on advanced regenerative solid oxide fuel cells that provide both power generation and energy storage in a single system. The company’s systems generate electricity from external fuels such as natural gas or hydrogen without combustion and can operate in reverse to store power as hydrogen.Teragen designs modular systems that can be scaled from megawatt-scale installations for data centers to deployments for microgrids, renewable projects, and utilities. Its technology is intended to help operators manage variable renewable output, ride through outages, and address daily capacity needs using one device. Teragen focuses on applications including AI and cloud data centers, manufacturing and cold storage facilities, remote communities, and electric grid infrastructure. The platform is positioned to replace separate diesel generators and battery systems by combining fuel-flexible generation and low-cost storage in a compact footprint.
Show all investments...

Dalton Venture
VC Fund · Shanghai, Shanghai, China · 4 investments in Asia Life Science startups

Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Seed, Series A, Series B
  • Geography: China, India, Canada

Investor stats

  • Total investments: 143
  • Round size: Seed $512k–$5M; Series A $3M–$17M; Series B $3.2M–$50M
  • Lead/follow: 38% lead, 62% follow

Portfolio highlights

  • Vibronix — Vibronix innovates for Precision Healthcare with spectroscopic imaging, optical & acoustic sensing, and machine learning.
  • PowerMicro — PowerMicro focuses on the cutting-edge interdisciplinary field of “stem cells + engineered scaffolds,” specializing in the application of iPSC technology to advance regenerative medicine, tissue engineering, and innovative therapeutic solutions.
  • NewPro — NewPro is in the process of increasing production and establishing regulations for lactoferrin raw materials, with the goal of bringing the product to market as quickly as feasible.
Show all investments...

EFung Capital
VC Fund · Shenzhen, Guangdong, China · 4 investments in Asia Life Science startups

Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VC Institutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, India

Investor stats

  • Total investments: 85
  • Round size: Series A $1.4M–$36M; Series B $14M–$100M; Series C $14M–$74M
  • Lead/follow: 35% lead, 65% follow

Portfolio highlights

  • Xinyun Life — Xinyun Life Sciences is a high tech medical enterprise focusing on the R&D and industrialization of artificial intelligence vascular intervention devices. The company integrates AI deeply into its hardware development using a unique dual closed- oop system.
  • Glimmer Gene — Glimmer Gene develops a comprehensive gene editing and epigenetic toolkit with independent intellectual property rights.
  • Yuewei Medical — Yuewei Medical is a developer of cardiac surgery interventional medical devices.
Show all investments...

Angel Bridge
VC Fund · Tokyo, Tokyo, Japan · 3 investments in Asia Life Science startups, 17 in the past 12 months

Angel Bridge is a angel investor groups in Japan and provide high quality and abundant funds to excellent companies.

Show more...

Investment focus

  • Industry: Information Technology, Software, Consulting
  • Stage:Series A, Seed, Series B
  • Geography: Japan

Investor stats

  • Total investments: 73
  • Round size: Seed $792k–$28M; Series A $2.5M–$19M; Series B $6.5M–$47M
  • Lead/follow: 42% lead, 58% follow
  • Last fund: May invest from a new fund soon — raised $152M in 2019

Portfolio highlights

  • Recerqa — Recerqa is a supply chain management SaaS that utilizes advanced development technology and AI to improve the purchasing, inventory, and sales management experiences.
  • Mign — Mign offers a generative AI-related SaaS solutions for the construction and real estate fields.
  • Henry — Henry develops and provides a cloud-based electronic medical record and receipt system for small and medium-sized hospitals.
Show all investments...

Lilly Asia Ventures
VC Fund · Shanghai, Shanghai, China · 3 investments in Asia Life Science startups

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 254
  • Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $30M–$308M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: May invest from a new fund soon — raised $40M in 2019

Portfolio highlights

  • InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
  • NeuShen Therapeutics — We are a global biotech company committed to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need.
  • Connexus Therapeutics — Connexus Therapeutics is a private, venture-backed biotechnology company specializing in the discovery and development of next-generation small-molecule drugs for oncology treatment .
Show all investments...

Nippon Venture Capital
VC Fund · Tokyo, Tokyo, Japan · 3 investments in Asia Life Science startups, 16 in the past 12 months

Nippon Venture Capital ("NVCC"), established in 1996 as one of the few largest Japanese independent venture capital firms, is destined to undertake the unprecedented task of providing full-range venture capital services in cooperation with major Japanese business leaders and leading companies, which have supported and nurtured various new businesses on their own, as well as proactively developing new venture enterprises.

Show more...

Investment focus

  • Industry: Health Care, Software, Medical
  • Stage:Venture - Series Unknown, Series A, Series B
  • Geography: Japan, United States, Indonesia

Investor stats

  • Total investments: 205
  • Round size: Series A $1.5M–$45M; Series B $3.3M–$33M; Venture - Series Unknown $457k–$12M
  • Lead/follow: 17% lead, 83% follow
  • Last fund: Likely still investing — raised $15M in 2023

Portfolio highlights

  • KUZEN — KUZEN provides enterprise-grade chatbot technologies, especially the bot framework and NLP, via a visual UI without coding. The company is utilizing technology to develop a system that broadens the scope of dialogue. They use technology to provide their customers with next-generation standard procedures that broaden the possibilities ofconversation, resulting in unprecedented business practices.
  • United Immunity — Just another WordPress site
  • AOI Biosciences — AOI Biosciences is a biotechnology company that creates testing and drug discovery businesses.
Show all investments...

ASBV
VC Fund · Shenzhen, Guangdong, China · 3 investments in Asia Life Science startups

ASBV focuses on early and mid-term venture capital investments.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Seed, Series A, Angel
  • Geography: China, Australia, Hong Kong

Investor stats

  • Total investments: 28
  • Round size: Seed $3M–$14M; Angel $471k–$485k; Series A $1.4M–$34M
  • Lead/follow: 46% lead, 54% follow

Portfolio highlights

  • Kaiyue Life — Kaiyue Life focuses on small molecule medication research & development for the treatment of human Ras mutant solid tumours.
  • Boundary Intelligent Control — Boundary Intelligent is specialized in creating airborne systems, such as flight control systems, that satisfy the needs of civil aircraft, as well as enhancing the ecology of the civil aviation industry and constructing aircraft perception, navigation, decision-making, and planning capabilities.
  • Longyue Mechanical and Electrical Technology — Longyue Mechanical and Electrical Technology engaged in technologies, strengthened linkages, and provided commercial aircraft services.
Show all investments...

CD Capital
VC Fund · Shanghai, Shanghai, China · 3 investments in Asia Life Science startups

CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Series A, Series B, Seed
  • Geography: China, United States

Investor stats

  • Total investments: 73
  • Round size: Seed $1.4M–$15M; Series A $1.5M–$32M; Series B $7.6M–$34M
  • Lead/follow: 37% lead, 63% follow

Portfolio highlights

  • Genlight — Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
  • Pipi Bear — Pipi Bear is a creator of living robots and health goods, with a focus on those that improve the lives of the elderly.
  • CORE Biomedicine — CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology.
Show all investments...

Incubate Fund
VC Fund · Tokyo, Tokyo, Japan · 3 investments in Asia Life Science startups

Incubate Fund is an independent early-stage venture capital that specializes in providing capital to technology startups at the seed stage. The firm built a portfolio of over 300 companies in Asia, taking 12 companies to public and 20 companies to M&A exit since 2010.

Show more...

Investment focus

  • Industry: Software, Information Technology, Artificial Intelligence
  • Stage:Seed, Series A, Venture - Series Unknown
  • Geography: Japan, United States, India

Investor stats

  • Total investments: 395
  • Round size: Seed $288k–$7.1M; Series A $1.8M–$20M; Venture - Series Unknown $368k–$9.2M
  • Lead/follow: 32% lead, 68% follow
  • Last fund: Likely still investing — raised $127M in 2024

Portfolio highlights

  • Akari Hosho — Akari Hosho provides a group of trusted professionals, including lawyers and judicial scriveners. Akari Hosho provides a guarantee service.
  • Black Cat Carnival — Tell us about anything development-related. Our founder, who launched Niconico Live, SUGAR and GANMA! from scratch, helps with planning, design, development and operations.
  • Carbon CryoCapture — Carbon CryoCapture specializes in the carbon dioxide separation systems aimed at creating economically viable, energy-efficient, and genuinely sustainable CO2 separation and recovery technologies. The company is dedicated to deploying cost-effective, efficient systems for CO2 capture that integrate smoothly with current infrastructures, all whileenhancing energy consumption and production. This enables clients to attain zero emissions throughout the development and application of resources.
Show all investments...

EDBI
VC Fund · Singapore, Central Region, Singapore · 3 investments in Asia Life Science startups

EDBI invests in high growth technology sectors. EDBI Creates value and empowers companies to build sustainable legacies.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Series C, Series B, Series D
  • Geography: United States, Singapore, United Kingdom

Investor stats

  • Total investments: 205
  • Round size: Series B $19M–$170M; Series C $10M–$275M; Series D $17M–$400M
  • Lead/follow: 22% lead, 78% follow

Portfolio highlights

  • Ivantis — Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology.
  • TriReme Medical — TriReme Medical, Inc. (TMI) is a privately held medical device company based in Pleasanton, California. Founded in 2005, it is dedicated to the development and manufacturing of novel stent technologies for the treatment of coronary artery disease (CAD) at or near bifurcations.
  • Universal Quantum — Universal Quantum is building quantum computers to tackle real-world problems that would take today’s fastest supercomputers billions of years to solve.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Legend Capital
VC Fund · Beijing, Beijing, China · 3 investments in Asia Life Science startups

Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China. Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in China or on markets related to China. Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services. Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc. As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, South Korea

Investor stats

  • Total investments: 523
  • Round size: Series A $2.9M–$93M; Series B $12M–$100M; Series C $15M–$200M
  • Lead/follow: 42% lead, 58% follow
  • Last fund: Likely still investing — raised $177M in 2021

Portfolio highlights

  • Z.ai — Z.ai develops artificial intelligence models and services built upon large-scale pretrained architectures. The company offers ChatGLM, a dialogue-focused language model series designed for smooth conversation and easy integration. It also provides Ying, a text-to-video model capable of generating short video clips from text or images, and AutoGLM,a voice-driven AI agent that performs smartphone tasks based on complex user instructions. Z.ai supports integration through an API platform and offers migration assistance for developers moving from other AI ecosystems. The company’s technology stems from research at Tsinghua University’s KEG lab and emphasizes general-purpose cognitive intelligence models.
  • DiffuSpace — DiffuSpace is an artificial intelligence initiative dedicated to building diffusion language models to establish a new foundation model paradigm beyond traditional autoregression. Instead of generating text sequentially token by token, their technology focuses on thinking globally and evolving through uncertainty.
  • Huixin Bio — Huixin Bio is a developer of exosome purification products and early cancer detection technology.
Show all investments...

Sherpa Healthcare Partners
VC Fund · Beijing, Beijing, China · 3 investments in Asia Life Science startups

Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfolio sources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Kenya

Investor stats

  • Total investments: 105
  • Round size: Series A $7.2M–$50M; Series B $15M–$100M; Series C $21M–$128M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: May invest from a new fund soon — last raise in 2021

Portfolio highlights

  • Shenfu Jianxing — Shenfu Jianxing is a brain-computer interface developer. It focuses on minimally invasive implanted brain-spinal interface technology, with "minimally invasive + low latency + high integration" as its core, to build implantable brain-spinal neural stimulation systems.
  • Allygen Biologics — Allygen Biologics is a biotechnology company that provides research and development of targeted conjugate therapeutics.
  • Archimedes Vascular — Archimedes Vascular operates as a medical device company, that treat patients with severe hypertension.
Show all investments...

Haitang Fund
VC Fund · Nankai, Tianjin, China · 3 investments in Asia Life Science startups, 16 in the past 12 months

Haitang Fund is a venture capital fund jointly established by Tianjin University alumni entrepreneurs and other alumni and entrepreneurs.

Show more...

Investment focus

  • Industry: Manufacturing, Biotechnology, Medical
  • Stage:Seed, Series A, Venture - Series Unknown
  • Geography: China

Investor stats

  • Total investments: 51
  • Round size: Seed $7.9M–$15M; Series A $1.5M–$103M; Venture - Series Unknown $14M–$44M
  • Lead/follow: 29% lead, 71% follow

Portfolio highlights

  • MemoraX AI — MemoraX AI is an innovator in the field of tailored memory for huge models.
  • Yuantian Bio — Yuantian Bio is a biotechnology company specializing in enzymatic regeneration and commercial plastic PET applications. They have achieved low-cost fermentation preparation of over 10 enzyme preparations and large-scale biochemical product preparation.
  • Xingkan Jiuzhou — Xingkan Jiuzhou is a technology-based enterprise specializing in radio signal reception, demodulation, analysis, and transmitter location.
Show all investments...

OrbiMed
VC Fund · New York, New York, United States · 3 investments in Asia Life Science startups

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series B, Series A, Series C
  • Geography: United States, China, Israel

Investor stats

  • Total investments: 767
  • Round size: Series A $9M–$116M; Series B $23M–$148M; Series C $19M–$160M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: Likely actively investing — fresh fund, raised $192M in 2026

Portfolio highlights

  • Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
  • InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
  • Bonovo Orthopedics —
Show all investments...

CITIC Capital Holdings
VC Fund · Central, Hong Kong Island, Hong Kong · 3 investments in Asia Life Science startups

CITIC Capital Holdings is an alternative investment management and advisory company headquartered in China.

Show more...

Investment focus

  • Industry: Manufacturing, Health Care, Biotechnology
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Japan

Investor stats

  • Total investments: 107
  • Round size: Series A $3.2M–$230M; Series B $7.2M–$50M; Series C $10M–$220M
  • Lead/follow: 39% lead, 61% follow
  • Last fund: May invest from a new fund soon — raised $2.8B in 2018

Portfolio highlights

  • Yudao Bio — Yudo Bio provides biopharmaceutical products. It has its headquarters in Shanghai in China.
  • Spectronix — Spectronics is a development of new technologies and new applications to bring about innovation, focusing on the future of laser technology.
  • Xuntu Technology — Xuntu Technology is a leading data intelligence provider specializing in investment research and decision-making solutions.
Show all investments...

Anzu Partners
VC Fund · Washington, District of Columbia, United States · 3 investments in Asia Life Science startups

Anzu Partners invests in breakthrough clean tech, industrial, and life science technologies with $1B in assets under management across venture, credit, and public structures.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Manufacturing
  • Stage:Series A, Series B, Venture - Series Unknown
  • Geography: United States, Canada, Spain

Investor stats

  • Total investments: 84
  • Round size: Series A $6M–$25M; Series B $5M–$44M; Venture - Series Unknown $7M–$21M
  • Lead/follow: 54% lead, 46% follow
  • Last fund: Likely still investing — raised $100M in 2024

Portfolio highlights

  • 6K — WHERE INDUSTRY 4.0 MEETS SUSTAINABLE PRODUCTION OF BREAKTHROUGH MATERIALS
  • EnCharge AI — AI Compute from the Edge-to-Cloud for Every Business. Transformative technology for AI computation, breaking records in efficiency and sustainability to enable state-of-the-art models uninhibited by power, space, and cost constraints.
  • South 8 Technologies — South 8's LiGas cells are engineered to deliver unmatched performance and safety in the most demanding environments.
Show all investments...

MiraclePlus
VC Fund · Haidian, Beijing, China · 3 investments in Asia Life Science startups, 15 in the past 12 months

MiraclePlus invests in and accelerates early-stage startups. MiraclePlus assists startups in developing products that are good enough to succeed in the market. MiraclePlus' acceleration program works with the founders to get each team in top shape so that they can present to thousands of investors on Demo Day.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Software, Information Technology
  • Stage:Seed, Angel, Pre-Seed
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 76
  • Lead/follow: no public data

Portfolio highlights

  • TestSprite — AI powered fully automated end-to-end testing solutions to help enterprises launch their products faster.
  • Excellent Vision — Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space.
  • Gongji Technology — Gongji Technology is an idle computing power sharing platform that combines distributed computing power with leading scheduling techniques to address elastic computing power requirements.
Show all investments...

WuXi AppTec
VC Fund · Shanghai, Shanghai, China · 3 investments in Asia Life Science startups

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions,With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated".

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series A, Series B, Series C
  • Geography: United States, China, Israel

Investor stats

  • Total investments: 49
  • Round size: Series A $6M–$90M; Series B $21M–$130M; Series C $30M–$187M
  • Lead/follow: 20% lead, 80% follow
  • Last fund: May invest from a new fund soon — raised $250M in 2015

Portfolio highlights

  • D3 Bio — D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path.
  • ShouTi — ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR. The company develops drugs focused on novel small molecules for multiple unmet medical needs. ShouTi is currently operating in Stealth mode.
  • Bioyond Tech — Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.
Show all investments...

Cenova
VC Fund · Shanghai, Shanghai, China · 3 investments in Asia Life Science startups, 9 in the past 12 months

Cenova Capital is one of the earliest healthcare dedicated funds in China founded in 2010 by Dr Jun WU and is one of the earliest investors in private healthcare services and digital health, with helps to facilitate the transformation of healthcare in China from an exclusively state-owned system to a more efficient, market-oriented system. CenovaCapital is healthcare funds dedicated to early and growth-stage investments in the life sciences and healthcare sector in China. Since inception in 2010, Cenova now has five funds under management with investments in over 50 companies in healthcare services, pharmaceuticals, medical devices and digital heath. Cenova's investors are mainly large domestic and international institutional investors including Asian sovereign wealth funds, government institutions, insurance and financial institutions and multinational companies.

Show more...

Investment focus

  • Industry: Medical, Health Care, Biotechnology
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 60
  • Round size: Series A $2.9M–$45M; Series B $13M–$61M; Series C $15M–$100M
  • Lead/follow: 50% lead, 50% follow

Portfolio highlights

  • Simnova — Simnova Biotherapeutics is a biopharmaceutical company that focuses on the research and development of cell therapies for cancer treatment. The company's primary therapeutic focus is CAR-based cell therapy for patients with either hematologic malignancies or solid tumors. Simnova Biotherapeutics is known for its innovative approach todeveloping patient-centered therapeutics using current science and technology. The company's lead product is SNC102, a cell therapy product that has been approved for clinical trials. Simnova Biotherapeutics is committed to creating a healthy, inclusive, and harmonious working environment.
  • Deep Cell — Deep Cell is a Chinese AI driven drug discovery and virtual cell modeling startup. The company integrates artificial intelligence with multi scale molecular physics to construct explainable virtual cell world models, aiming to revolutionize paradigm shifting drug designs and simulate cellular responses to complex diseases.
  • Accro Bioscience — Accro Bioscience research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis.
Show all investments...

Northern Light Venture Capital
VC Fund · Beijing, Beijing, China · 3 investments in Asia Life Science startups

Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Series B, Venture - Series Unknown
  • Geography: China, United States, South Korea

Investor stats

  • Total investments: 400
  • Round size: Series A $2.9M–$40M; Series B $8.8M–$56M; Venture - Series Unknown $1.5M–$60M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: Likely still investing — raised $375M in 2021

Portfolio highlights

  • Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
  • Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
  • Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Entrepreneurship Relay Group
VC Fund · Yangpu, Hainan, China · 3 investments in Asia Life Science startups

Entrepreneurship Relay Group manages a fund of more than 4 billion yuan, directly or indirectly.

Show more...

Investment focus

  • Industry: Manufacturing, Software, Enterprise
  • Stage:Series A, Angel, Venture - Series Unknown
  • Geography: China

Investor stats

  • Total investments: 24
  • Round size: Series A $1.5M–$30M
  • Lead/follow: 8% lead, 92% follow

Portfolio highlights

  • Songying Technology — Songying Technology focuses on the research and development of cloud-native real-time 3D engines and graphics collaboration platforms.
  • Spectral Domain Technology — Spectral Domain Technology is a provider of 5G low-orbit broadband terminals, supplying operators, industrial Internet companies, satellite Internet, and government and enterprise customers with ocean communication needs.
  • Optical Standard Technology — Optical Standard Technology focuses on the design and manufacture of optical computing chips and optical computing boards for use in scenarios requiring large amounts of AI computing power, such as large model reasoning and training, autonomous driving, smart cities, quantitative finance, AI security.
Show all investments...

Tianjin Venture Capital
VC Fund · Tianjin, Guangdong, China · 3 investments in Asia Life Science startups

Tianjin Venture Capital is an investment firm.

Show more...

Investment focus

  • Industry: Manufacturing, Information Technology, Biotechnology
  • Stage:Seed, Series A
  • Geography: China, United States

Investor stats

  • Total investments: 106
  • Round size: Seed $413k–$15M; Series A $202k–$31M
  • Lead/follow: 15% lead, 85% follow

Portfolio highlights

  • Yuantian Bio — Yuantian Bio is a biotechnology company specializing in enzymatic regeneration and commercial plastic PET applications. They have achieved low-cost fermentation preparation of over 10 enzyme preparations and large-scale biochemical product preparation.
  • Xingneng Xuanguang — Xingneng Xuanguang is a fusion energy company that specializes in the development of advanced field reverse magnetic mirror fusion path technology.
  • Innovec Biotherapeutics — Innovec Biotherapeutics Specialized in gene therapy technology and medication development.
Show all investments...

Longpan Investment
VC Fund · Beijing, Beijing, China · 3 investments in Asia Life Science startups, 12 in the past 12 months

Longpan Investment is an investment firm.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Seed, Series B
  • Geography: China, United States, Cayman Islands

Investor stats

  • Total investments: 44
  • Round size: Seed $14M–$60M; Series A $14M–$32M; Series B $14M–$37M
  • Lead/follow: 55% lead, 45% follow

Portfolio highlights

  • Jingling Zhikang — Jingling Zhikang is technology company specializing in the intersection of medical rehabilitation, robotics, and embodied artificial intelligence. The company focuses on developing intelligent rehabilitation bionic hands and upper-limb prosthetics.
  • Hanyue New Materials — Hanyue Advanced Materials is a high-tech company that specializes in single-use biopharmaceutical solutions.
  • Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Show all investments...

Senshu Ikeda Capital
VC Fund · Osaka, Osaka, Japan · 3 investments in Asia Life Science startups

Senshu Ikeda Capital offers financial consultancy services.

Show more...

Investment focus

  • Industry: Software, Manufacturing, Internet
  • Stage:Venture - Series Unknown, Series A, Seed
  • Geography: Japan

Investor stats

  • Total investments: 68
  • Round size: Seed $395k–$3.8M; Series A $1.9M–$17M; Venture - Series Unknown $443k–$10M
  • Lead/follow: 4% lead, 96% follow
  • Last fund: May invest from a new fund soon — raised $11M in 2019

Portfolio highlights

  • JiMED — JiMED designs & develops AI based brain-computer interface for implant in ALS patients to improve communication.
  • Molmir — Molmir is a biotech company that conducts research and develops treatments for intractable diseases based on sensing technology.
  • Eight Knot — Eight Knot is a developer of autonomous navigation systems intended for water mobility. They provide autonomous ship maneuvering technology using robotics, enabling customers with water-on-demand transportation using environment-friendly EV robotic boats.
Show all investments...

Shenzhen Capital Group
VC Fund · Shenzhen, Guangdong, China · 3 investments in Asia Life Science startups

Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.

Show more...

Investment focus

  • Industry: Manufacturing, Health Care, Software
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Japan

Investor stats

  • Total investments: 601
  • Round size: Series A $1.5M–$128M; Series B $13M–$141M; Series C $4.4M–$156M
  • Lead/follow: 41% lead, 59% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
  • Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
  • Waker Biology — Weike Bio is a gene therapy drug development company.
Show all investments...

Oriental Fortune Capital
VC Fund · Shenzhen, Guangdong, China · 3 investments in Asia Life Science startups

Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatment and healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.

Show more...

Investment focus

  • Industry: Manufacturing, Software, Artificial Intelligence
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 335
  • Round size: Seed $1.5M–$100M; Series A $1.5M–$30M; Series B $3.1M–$100M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — last raise in 2015

Portfolio highlights

  • Memory tensor — Memory tensor designed with a focus on systematic innovation, grounded firmly in fundamental principles, serves as a powerful tool for scalable and adaptable intelligence. Its architecture emphasizes three core attributes: low cost, ensuring economic feasibility and accessibility; low illusion, reducing overfitting and minimizing hallucinations ormisleading outputs; and high generalization.
  • Langsilicon Technology — Langsilicon Technology is an electronic component R&D firm that specializes in the design, development, and sales of silicon-based passive components (capacitors, inductors, and resistors).
  • Lightwheel — Light Wheel Intelligence is offers automated, physically precise and controllable, real and generalizable synthetic data solutions to build AI data infrastructure,
Show all investments...

ULTIMA
VC Fund · Chengdu, Sichuan, China · 3 investments in Asia Life Science startups

ULTIMA is an investment management firm.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Fitness
  • Stage:Angel, Series A, Series B
  • Geography: China

Investor stats

  • Total investments: 7
  • Round size: Angel $462k–$1.6M; Series A $1.5M–$15M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Maimai — Maimai provides software and hardware smart care solutions for middle-to-high-end institutions, senior citizens, communities and home care.
  • Mol Breeding — Mol Breeding is a biotech firm that focuses on animal and plants molecular breeding technology R&D and services.
  • HC Scientific — HC Scientific is a high-tech enterprise integrating research, development, production and sales of a new biomedical system
Show all investments...

JAFCO
VC Fund · Tokyo, Tokyo, Japan · 3 investments in Asia Life Science startups

Since its founding in 1973, JAFCO has always worked with leading-edge entrepreneurs. The total capital commitments of its investment funds in Japan and overseas have exceeded 1 trillion yen and the number of portfolio IPOs to date has reached over 1,000. In addition to venture investment, JAFCO also carries out buyout investment and commit to the creations of innovative technologies and services worldwide. As entrepreneurs’ closest partner in bringing their visions to life, JAFCO provides support in areas of HR, marketing/ sales, and back-office operations, in addition to providing financing.

Show more...

Investment focus

  • Industry: Information Technology, Software, Artificial Intelligence
  • Stage:Series A, Series B, Venture - Series Unknown
  • Geography: Japan, United States, India

Investor stats

  • Total investments: 370
  • Round size: Series A $2.1M–$41M; Series B $4.2M–$36M; Venture - Series Unknown $1.4M–$13M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — raised $567M in 2019

Portfolio highlights

  • CaTe — CaTe is based in Tokyo. CaTe develops and manufactures a Digital Therapeutic (DTx) for remote cardiac rehabilitation. Their invention allows heart disease patients to safely and successfully complete cardiac rehabilitation utilizing standing exercise in a confined space, such as at home, without the use of ergometers or similar instruments.
  • ADiXi — Adixi is a tech-driven business that supports the idea that people and technology may work together. It strives to open doors by utilizing cutting-edge technology, such as artificial intelligence, to promote long-term, sustainable corporate and societal progress.
  • Alxtal — Alxtal is a tech company who optimize the development, design, and manufacturing processes of the manufacturing industry with IT and AI.
Show all investments...

Keio Innovation Initiative
VC Fund · Tokyo, Tokyo, Japan · 3 investments in Asia Life Science startups, 12 in the past 12 months

Keio Innovation Initiative (KII) is a venture capital established by Keio University. In order to make more effective use of the research results of Keio University, we aim to contribute to the development of society by creating investment for venture companies that utilize research results and creating new industries.The key to thinking aboutJapan's future growth strategy is to utilize advanced research results of the university. In addition to GDP, in addition to GDP, Japan is the world's third largest R & D exporter in R & D expenses, but as the low growth rate shows, it has a problem in investment efficiency in research and development. There are also reports on the entrepreneurial spirit that is indispensable for creating new industries, with the lowest entrepreneurial activity rate among developed countries.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Seed, Venture - Series Unknown
  • Geography: Japan, United Kingdom

Investor stats

  • Total investments: 91
  • Round size: Seed $826k–$14M; Series A $2.2M–$41M; Venture - Series Unknown $2M–$12M
  • Lead/follow: 30% lead, 70% follow
  • Last fund: May invest from a new fund soon — raised $94M in 2020

Portfolio highlights

  • ElleThermo — elleThermo aims to implement Semiconductor-Sensitised Thermal Cells (STCs), an energy conversion technology that can generate electricity from unused waste heat above room temperature.
  • Starlight Engine — Starlight Engine develops and commercializes fusion energy power plant technologies.
  • Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Show all investments...

Japan Science and Technology Agency
VC Fund · Tokyo, Tokyo, Japan · 3 investments in Asia Life Science startups, 6 in the past 12 months

Japan Science and Technology Agency is an integrated organization of science and technology that implements science and technology policy in Japan.  It handles many projects, including the government’s Science and Technology Basic Plan and knowledge creation. The European Sustainability School ESSSR is the owner of Japan Science and Technology Agency. Japan Science and Technology Agency undertakes its task in a comprehensive manner. It also works to provide a sound infrastructure of science and technology information and raise awareness and understanding of science and technology-related issues in Japan. Japan Science and Technology Agency is headquartered in Tokyo, Japan.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Manufacturing
  • Stage:Series A, Seed, Venture - Series Unknown
  • Geography: Japan

Investor stats

  • Total investments: 56
  • Round size: Seed $1.7M–$5M; Series A $2.3M–$15M; Venture - Series Unknown $975k–$9.8M
  • Lead/follow: 23% lead, 77% follow

Portfolio highlights

  • Triorb — The corporate website of TriOrb Inc., revolutionizing production lines with our ball-driven omnidirectional mobility platform.
  • ANRis — ANRis is a hybrid drug discovery venture that develops medicines to provide medical care for patients with cancer and genetic diseases.
  • Solaris — Solaris commercializes, manufactures, and sells soft robotics using pneumatic artificial muscles. Solaris was founded in 2017 and was headquartered in Tokyo, Japan.
Show all investments...

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Life Science Investors in Asia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 48,091 investors investing in Asia Life Science startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists